Ten-year expericence of percutaneous radiofrequency ablation for hepatocelluar carcinoma. Background: OSI-Tar 725 is a phase II study assessing the efficacy of erlotinib, dosed to achieve a rash, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results